The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Blinatumomab as last consolidation prior to allo-HSCT in pediatric and young adult patients with B-cell ALL
|
A single-center, retrospective analysis assessed the outcomes of 78 pediatric and young adult patients with B-ALL who were treated with blinatumomab, a bispecific T-cell engager, as last consolidation therapy prior to allo-HSCT at Bambino Gesù Children's Hospital, IT.1 Results from this analysis were published in Haematologica by Algeri et al.1 |
| Key learnings |
| At a median follow-up of 23.2 months, the 2-year DFS, OS, CIR, and cumulative incidence of NRM rates were 72.2%, 89.2%, 25.2%, and 2.6%, respectively. |
| There was a trend towards improved 2-year DFS (92.9% vs 68.5%; p = 0.18) and lower CIR (0% vs 29.9%; p = 0.05) in patients transplanted in CR1 vs CR2/CR3. |
| The cumulative incidence of Grade II–IV aGvHD and cGvHD were 12.8% and 13%, with a 2-year GRFS rate of 68.4%. There were no recorded cases of SOS or TMA. |
| Results from this analysis suggest that blinatumomab is well-tolerated and effective as a pre-transplant treatment for pediatric and young adult patients with B-ALL. |
Abbreviations: aGvHD, acute graft-versus-host disease; allo-HSCT, allogeneic hematopoietic stem cell transplantation; B-ALL, B-cell acute lymphoblastic leukemia; cGvHD, CIR, cumulative incidence of relapse; chronic graft-versus-host disease; CR, complete remission; DFS, disease-free survival; GRFS, graft-versus-host disease-free relapse-free survival; NRM, non-relapse mortality; SOS, sinusoidal obstruction syndrome; TMA, transplant-associated microangiopathy.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
